Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (NASDAQ: TIVC) is a pioneering health technology company dedicated to transforming bioelectronic medicine. Our core mission is to develop and commercialize non-invasive products that activate the body’s natural healing mechanisms. Headquartered in San Francisco, Tivic Health is at the forefront of delivering innovative solutions for therapeutic benefit, predominantly focusing on sinus pain relief.
Our flagship product, ClearUP Sinus Relief, is a patented handheld device designed to alleviate sinus pain and congestion using ultra-low electrical currents. This device offers a natural alternative to conventional treatments like nasal sprays, pills, and saline flushes, and is particularly beneficial for individuals suffering from nasal allergies, sinus infections, chronic sinusitis, and the common cold.
Our latest innovation, Synus, provides temporary relief from sinus pain and pressure through microcurrents. This product represents our commitment to offering non-pharmaceutical options to those seeking effective and convenient sinus pain management.
With an emphasis on safety and efficacy, Tivic Health is not only advancing bioelectronic medicine but also setting new standards in patient care. Our team of dedicated professionals continually explores the therapeutic potential of microcurrents, aiming to expand our product line to treat various medical conditions in the future. We are committed to enhancing the quality of life for our users by providing accessible and effective health solutions.
For the latest updates and developments, stay tuned to our Latest News section and follow our progress as we continue to innovate and grow in the exciting field of bioelectronic medicine.
Tivic Health Systems, Inc. (TIVC) announced that its ClearUP® Sinus Pain Relief device has been awarded the Most Innovative Sinus Relief Solution for 2022 by Global Health & Pharma. This recognition marks the second consecutive year for ClearUP, which is FDA-cleared and clinically proven to alleviate sinus pain and congestion. The company aims to further develop bioelectronic treatments for various conditions, reflecting a shift towards non-invasive medical solutions. Recent accolades enhance Tivic's visibility in the health tech space, signaling strong market potential.
Tivic Health Systems (Nasdaq: TIVC) announced its Annual General Meeting of Shareholders to be held virtually on June 14, 2022, at 10:00 AM PDT. This format aims to ensure accessibility for all shareholders. Related documents and information can be found on Tivic Health's website and the SEC's website. The company specializes in non-invasive bioelectronic treatments for inflammation and related conditions. Forward-looking statements in the release highlight inherent risks and uncertainties affecting future performance.
Tivic Health Systems, Inc. (TIVC) reported a strong first quarter 2022 with a 33% increase in net revenue to $428K compared to $323K in Q1 2021. Notably, gross profit surged 219% to $70K, driven by a 77% growth in direct-to-consumer unit sales. Overall unit sales rose by 28%, aided by the termination of less profitable retail arrangements. However, total expenses rose significantly, including $684K in sales and marketing, reflecting increased advertising and e-commerce efforts. Cash reserves stood at approximately $10.8 million as of March 31, 2022.
Jennifer Ernst, CEO of Tivic Health, will speak at FORTUNE Brainstorm Health on May 11, participating in a panel titled Driving Digital Health: Where Wearables Are Headed Next. The event, held in Los Angeles on May 10-11, 2022, focuses on the intersections of health care and technology, highlighting innovations that enhance health outcomes. Ernst's recent accolades include recognition as one of the Inc 100 Female Founders and a leader in Consumer Healthcare.
For more on Tivic Health, visit tivichealth.com.
Tivic Health Systems, Inc. (Nasdaq: TIVC) will report its Q1 2022 financial results on May 16, 2022, at 1:30 pm PT (4:30 pm ET) via conference call and webcast. Investors can access the call at this link. The company focuses on non-invasive bioelectronic treatments for inflammation and related conditions. For further information, visit Tivic Health's website.
Tivic Health® Systems, Inc. (Nasdaq: TIVC) announced its fourth quarter 2021 financial results and year-end shareholder update via conference call on April 19, 2022. The call is scheduled for 2:00 pm PT / 5:00 pm ET, providing insights into the company’s performance in the bioelectronic medicine sector. Interested participants can join by calling the toll-free number 888-506-0062 or the international number 973-528-0011 with the access code 689084. Tivic Health focuses on non-invasive treatments for inflammation and related conditions.
Tivic Health Systems (Nasdaq: TIVC) announced key executive appointments, effective April 1, 2022.
Tivic Health (Nasdaq: TIVC), a healthtech company specializing in bioelectronic medicine, was featured in an ABC News story highlighting new bioelectronic technologies for managing conditions like sinus pain and arthritis. ClearUP® Sinus Pain Relief, the only commercially available product showcased, is part of the company's growth strategy following a $17.2 million IPO in November 2021. The company is advancing its Gen2 product and exploring new applications in bioelectronic therapies as alternatives to opioids.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
What is Tivic Health Systems, Inc.?
What does Tivic Health specialize in?
What is the ClearUP Sinus Relief device?
How does Tivic Health's technology work?
What conditions does ClearUP Sinus Relief treat?
What is Synus?
How is Tivic Health different from pharmaceutical companies?
Where can I learn more about Tivic Health's products?
Why choose Tivic Health products?
What are the future plans for Tivic Health?
